Nagamine T, Takagi H, Takayama H, Kojima A, Kakizaki S, Mori M, Nakajima K
Department of Health Science, Gunma University School of Medicine, Maebashi, Japan.
Biol Trace Elem Res. 2000 Summer;75(1-3):53-63. doi: 10.1385/BTER:75:1-3:53.
We have evaluated the efficacy of interferon-alpha (IFN-alpha) plus zinc therapy in hepatitis C patients with genotype 1b, poor responders for IFN alone. Ten patients were injected with 10 MU of IFN-alpha every day for 4 wk, followed by three times a week for 20 wk (control group). Nine patients took 300 mg of zinc sulfate a day orally during IFN-alpha therapy (zinc sulfate group), and 15 patients took IFN-alpha and 150 mg of polaprezinc (polaprezinc group). On the d 8 of IFN therapy, circadian zinc levels in serum elevated significantly in the polaprezinc group compared to the zinc sulfate group or control group. Serum ALT levels normalized in 73.3% of the polaprezinc group, 55.6% of the zinc sulfate group, and 40.0% of the control group at 6 mo after the end of IFN therapy. Sustained eradication for the hepatitis C virus RNA judged at the end of the 6-mo follow-up period was higher in the polaprezinc group than in the zinc sulfate group (53.3% vs 11.1%, p < 0.05) or the control group (20.0%). No clinical side effects of zinc were observed at the dose used. The data suggest that polaprezinc is expected to increase the therapeutic response of IFN-alpha for chronic hepatitis C with genotype 1b.
我们评估了干扰素-α（IFN-α）联合锌疗法对基因1b型丙型肝炎患者（单独使用IFN疗效不佳者）的疗效。10名患者每天注射10 MU的IFN-α，共4周，随后每周3次，共20周（对照组）。9名患者在IFN-α治疗期间每天口服300 mg硫酸锌（硫酸锌组），15名患者使用IFN-α和150 mg聚普瑞锌（聚普瑞锌组）。在IFN治疗的第8天，与硫酸锌组或对照组相比，聚普瑞锌组血清中的昼夜锌水平显著升高。IFN治疗结束后6个月时，聚普瑞锌组73.3%的患者血清ALT水平恢复正常，硫酸锌组为55.6%，对照组为40.0%。在6个月随访期结束时判断的丙型肝炎病毒RNA持续清除率，聚普瑞锌组高于硫酸锌组（53.3%对11.1%，p<0.05）或对照组（20.0%）。在所使用的剂量下未观察到锌的临床副作用。数据表明，聚普瑞锌有望提高IFN-α对基因1b型慢性丙型肝炎的治疗反应。
